Clinical trials: NSCLC Stage II
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Prostate Cancer
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, Non Small Cell Lung Cancer
- Trial name
- NeoFIND (NCT03724253)
- Testing
- [68Ga]-NeoBOMB1
- Where
- 3 sites in Austria, France
- Volunteers
- 19 people
- Sponsor
- Advanced Accelerator Applications
Lung Cancer
Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if proton radiotherapy given with standard chemotherapy (such as paclitaxel and carboplatin) can help to control locally advanced NSCLC.
- Trial name
- NCT00495170
- Testing
- Carboplatin, Proton Radiotherapy, Paclitaxel
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
This study will evaluate the efficacy and safety of chemotherapy given prior to having lung cancer surgically removed. Patients with resectable non-small cell lung cancer will receive gemcitabine and pemetrexed together for 4…
- Trial name
- NCT00226577
- Testing
- Gemcitabine, Pemetrexed, Surgery
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- BIRCH (NCT02031458)
- Testing
- Atezolizumab
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 667 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based expression profile to determine chemotherapy sensitivity in completely resected early stage non-squamous…
- Trial name
- TOP0703 (NCT00545948)
- Testing
- Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Non-small Cell Lung Cancer
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
This is an open-label, non-randomized, phase II clinical research study designed to assess the safety and efficacy of nivolumab and ipilimumab in combination with paclitaxel in patients with treatment naïve NSCLC.
- Trial name
- TOP1705 (NCT03573947)
- Testing
- Nivolumab, Ipilimumab, Paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Jeffrey Clarke
Previously Treated Non Small Cell Lung Cancer
A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell Lung Cancer Patients
- Trial name
- NCT02087176
- Testing
- AZD1775, Antimitotic Agent, pegfiligrastim
- Where
- 12 sites in United States
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Lung Cancer
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
The purpose of this study is to determine the response rate by RECIST criteria of oral dichloroacetate in patients with recurrent and/or metastatic and pretreated breast and non-small cell lung cancer.
- Trial name
- NCT01029925
- Testing
- Dichloroacetate (DCA)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer, Small Cell Lung Cancer
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00527735
- Testing
- Ipilimumab, Paclitaxel, Carboplatin
- Where
- 72 sites in United States, France and 6 more
- Volunteers
- 334 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Sunitinib Non Small Cell Lung Cancer Patients Over 70
The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.
- Trial name
- NCT00864721
- Testing
- Sutent
- Where
- 13 sites in United States
- Volunteers
- 63 people
- Sponsor
- US Oncology Research
Stage IV Non-Small Cell Lung Cancer
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
The goal of this clinical trial is to determine if low single palliative dose radiation to the lung cancer will improve your immune response against the tumor and if sequential treatment with pembrolizumab (the study drug) would…
- Trial name
- NCT02658097
- Testing
- Pembrolizumab, Single Fraction Radiation Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancer
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00326599
- Testing
- carboplatin, cediranib maleate, gemcitabine hydrochloride
- Where
- 154 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to evaluate the effectiveness of Tarceva® (OSI-774, erlotinib hydrochloride) in combination with Targretin® (bexarotene) in treating NSCLC.
- Trial name
- NCT00411632
- Testing
- Bexarotene, Erlotinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
This study is to determine that pembrolizumab is safe and tolerable at the selected dose for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with a performance status of 2. All patients will receive pembrolizumab.
- Trial name
- PePS2 (NCT02733159)
- Testing
- pembrolizumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Birmingham
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
The aim of this study is to combine AZD1775 with standard front-line chemotherapy in subjects with advanced NSCLC.
- Trial name
- NCT02087241
- Testing
- AZD1775, pemetrexed, carboplatin
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.
- Trial name
- NCT00063154
- Testing
- Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Non-Small Cell Lung Cancer
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
- Trial name
- NCT03003468
- Testing
- Imprime PGG, MK-3475
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Lawrence Feldman, MD
Non-Small Cell Lung Cancer
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
- Trial name
- NCT00271505
- Testing
- Bevacizumab (Avastin), Carboplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Non-small Cell Lung Cancer
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and…
- Trial name
- NCT01102231
- Testing
- Chemotherapy, ERBITUX, Radiotherapy
- Where
- 38 sites in France
- Volunteers
- 106 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique